Fig. 1 · Structure

Documents & Downloads

Megestrol Acetate

Cat. No. A10563 CAS 595-33-5
Megestrol Acetate is a progesterone derivative with antineoplastic properties

In Stock

Publications for Megestrol Acetate

1 publication citing this product

  1. Hong Wang, .et al. , Exp Biol Med (Maywood), 2021, Jul 7 PMID: 34233525

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Megestrol acetate showed progestogenic transcriptional activity in T47D breast cancer cells: 100 nM for 8 h increased the PR-regulated transcripts FKBP5 and E2F1 relative to ethanol vehicle. This functional assay does not measure receptor-binding affinity. [1]

Megestrol acetate also elicited glucocorticoid-like transcription in MDA-MB-231 cells. At 1 μM for 4 h, it increased SGK1 and GILZ expression in an assay with dexamethasone as positive control. These responses establish activity in this model without demonstrating receptor selectivity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
progestogen Receptor
Androgen Receptor

Megestrol Acetate Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of Megestrol Acetate from 3 published references.

Megestrol Acetate In Vitro Studies

In human adipose-derived stem cells, megestrol acetate increased the proliferation-associated CCK-8 readout at 10 μM after 48 h. A separate GR knockdown experiment attenuated MA-stimulated proliferation compared with control siRNA, supporting GR involvement. Cells were sourced from two women; donor-level reproducibility and an in-vivo regenerative benefit were not established. [2]

PR-regulated transcription in T47D cells

Cell-based study · T47D human breast cancer cells, charcoal-stripped serum medium for 48 h before treatment [1]

MA increased FKBP5 and E2F1 transcript abundance relative to ethanol vehicle. R5020 served as a progesterone-agonist control. This is a functional transcription assay; it does not establish binding affinity, an EC50, or receptor exclusivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
FKBP5 and E2F1 transcript abundance relative to ethanol vehicleMean mRNA fold change FKBP5: 8.9; E2F1: 4.8; triplicate determinations[1]

Literature-Reported Treatment Conditions

Treatment concentration
MA 100 nM; positive control R5020 10 nM
Exposure duration
8 h
Method
Cell treatment followed by TaqMan real-time PCR; expression normalized to ethanol-treated cells
Vehicle
Ethanol
Co-treatment
None in the selected MA arm
Reported limits
Ethanol percentage and biological independence of triplicate determinations are not specified in the selected assay description. SD versus SE labeling is inconsistent; no ± estimate is adopted.
Methods and source locations

Compound reported in the paper: Megestrol acetate; Compound label in the paper: MA

Experimental findings for the named acetate form; no equivalence to an Adooq lot or clinical formulation is established.

Methods: Chemicals and reagents; Progesterone receptor (PR) activity; Data analysis. Results: MA activity on the PR; Figure 6B–C.

FKBP5 and E2F1 transcript abundance relative to ethanol vehicle: TaqMan real-time PCR; Figure 6B–C marks both MA comparisons **p<0.01 versus vehicle — Results: MA activity on the PR, reported means; Figure 6B–C and caption; Methods: PR activity

GR-associated transcription in MDA-MB-231 cells

Cell-based study · MDA-MB-231 human triple-negative breast cancer cells; 2.5% charcoal-stripped FCS conditioning for 48 h [1]

MA increased SGK1 and GILZ transcript abundance in an assay using dexamethasone as positive control. The endpoints support glucocorticoid-like transcriptional activity in this model, without establishing receptor selectivity or an antitumor effect.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
SGK1 and GILZ transcript abundance relative to vehicleMean mRNA fold change MA: SGK1 9.0, GILZ 21.2; dexamethasone: SGK1 5.6, GILZ 18.5; triplicate determinations[1]

Literature-Reported Treatment Conditions

Treatment concentration
MA 1 μM; positive control dexamethasone 0.1 μM
Exposure duration
4 h
Method
Cell treatment and quantitative real-time PCR, GR target expression normalized to β-actin
Vehicle
Ethanol
Co-treatment
None in the selected MA arm
Reported limits
Final ethanol percentage and biological independence of triplicate determinations are not specified; Figure 8 supplies no numerical error estimates.
Methods and source locations

Compound reported in the paper: Megestrol acetate; Compound label in the paper: MA

Experimental findings for the named acetate form; no equivalence to an Adooq lot or clinical formulation is established.

Methods: Chemicals and reagents; Glucocorticoid receptor (GR) activity. Results: MA activity on the GR; Figure 8A–B.

SGK1 and GILZ transcript abundance relative to vehicle: Quantitative real-time PCR; numerical means from Results, not estimated from plotted bars — Results: MA activity on the GR; Figure 8A–B and caption; Methods: GR activity

Proliferation-associated response in human ASCs

Cell-based study · Human adipose-derived stem cells obtained from subcutaneous liposuction samples from two healthy women [2]

MA 10 μM increased the proliferation-associated CCK-8 readout versus no MA in human ASCs. This endpoint is a colorimetric proxy, not direct division tracking.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Proliferation-associated CCK-8 readoutDirection and reported significance Increased with MA 10 μM versus no MA; p < .01; n = 3[2]

Literature-Reported Treatment Conditions

Treatment concentration
MA 10 μM (selected comparison; Figure 1A also tests 1, 5 and 50 μM)
Exposure duration
48 h
Method
0.2% FBS culture; CCK-8 proliferation assay
Co-treatment
None in the selected comparison
Reported limits
MA stock solvent, final vehicle concentration, supplier and lot are not specified in the acquired main text. No exact proliferation means or error estimates are extracted from bars.
Methods and source locations

Compound reported in the paper: Megestrol acetate; Compound label in the paper: MA

Experimental findings for the named acetate form; no equivalence to an Adooq lot or clinical formulation is established.

Methods: Cell Culture; Cell Proliferation Assay; Statistical Analysis. Results: Progesterone and MA Increased the Proliferation and Migration of ASCs; Figure 1A.

Proliferation-associated CCK-8 readout: CCK-8, 48 h; 450 nm absorbance — Methods: Cell Proliferation Assay; Results: Progesterone and MA Increased the Proliferation and Migration of ASCs; Figure 1A

GR knockdown validation of MA-stimulated ASC proliferation

Cell-based study · Human adipose-derived stem cells obtained from subcutaneous liposuction samples from two healthy women [2]

GR-targeting siRNA reduced GR mRNA and attenuated MA-stimulated proliferation compared with control siRNA. The MA concentration for Figure 6B is not explicitly specified in its caption or associated Results, so the validation is not assigned the 10 μM dose used in the separate Figure 1A comparison.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
GR knockdown and MA-induced proliferationPerturbation validation siGR reduced GR mRNA and attenuated MA-induced proliferation; p < .01; n = 3[2]

Literature-Reported Treatment Conditions

Treatment concentration
GR siRNA 50 nM; MA concentration for Figure 6B not explicitly specified
Exposure duration
siRNA transfection: 24 h; proliferation assay method specifies MA exposure for 48 h
Method
siGR#1 versus control siRNA; GR mRNA knockdown assessed by qPCR; CCK-8 proliferation assay
Co-treatment
MA with GR-targeting siRNA versus MA with control siRNA in the validation experiment
Reported limits
The MA concentration for Figure 6B is not explicitly specified. MA solvent, supplier and lot are not specified in acquired main text. Exact proliferation values are not inferred from bars.
Methods and source locations

Compound reported in the paper: Megestrol acetate; Compound label in the paper: MA

Experimental findings for the named acetate form; no equivalence to an Adooq lot or clinical formulation is established.

Methods: Cell Culture; Cell Proliferation Assay; Small Interfering RNA Transfection; Statistical Analysis. Results: GR Silencing Attenuated MA-Induced Stimulation; Figure 6A–B.

GR knockdown and MA-induced proliferation: qPCR validation of GR knockdown and CCK-8 comparison of siCON/siGR with and without MA; no exact percentages inferred — Methods: Small Interfering RNA Transfection; Results: GR Silencing Attenuated MA-Induced Stimulation; Figure 6A–B

Megestrol Acetate In Vivo Studies

In male rats with tumor-associated cachexia, megestrol acetate at 100 mg/kg/day by gavage improved left ventricular ejection fraction and survival compared with tumor-bearing placebo. The survival hazard ratio was 0.44 (95% CI 0.20–1.00; reported P = 0.0486). Food intake improved, but spontaneous activity, stroke volume and end-diastolic volume did not. Tumor growth was not significantly affected. These findings come from a maximum 16-day experiment. [3]

Cardiac and survival outcomes in cachectic rats

Animal study · Eight-week-old male Wistar Han rats with Yoshida AH-130 hepatoma-associated cachexia; tumor-bearing placebo n=11, MA n=10; saline sham n=11 [3]

In one randomized, operator-blinded experiment, MA improved selected cardiac endpoints and survival compared with tumor-bearing placebo. Food intake increased but spontaneous activity did not improve; stroke volume and end-diastolic volume also failed to improve. No statistically significant tumor-growth effect was found.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Left ventricular ejection fraction on day 11Mean ± SEM (%) MA 73.5 ± 5%; tumor-bearing placebo 58.7 ± 2%; sham 75.4 ± 2%; MA versus placebo P < 0.05[3]
Survival over maximum 16-day studyHazard ratio (95% CI) 0.44 (95% CI: 0.20–1.00); P = 0.0486[3]
Food intake, spontaneous activity, cardiac volumes and tumor growthDirection and limiting findings Food intake increased (P < 0.05 vs placebo); no activity improvement; no improvement in LV stroke volume or end-diastolic volume; no statistically significant tumor-growth effect[3]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Once daily
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Megestrol acetate
100 mg/kg/day
Tumor-bearing placeboLVEF 73.5 ± 5% (mean ± SEM); survival HR 0.44 versus placebo[3]
Tumor-bearing placeboComparator for MALVEF 58.7 ± 2% (mean ± SEM)[3]
Megestrol acetate
Model: Tumor-bearing male Wistar Han rats; n=10
Treatment course: Up to 16 days; MA started one day after tumor inoculation
Reported limits: Drug/placebo composition and supplier are not specified in the acquired main text.
Tumor-bearing placebo
Model: Tumor-bearing male Wistar Han rats; n=11
Treatment course: Up to 16 days, beginning one day after tumor inoculation
Reported limits: Drug/placebo composition and supplier are not specified in the acquired main text.
Methods and source locations

Compound reported in the paper: Megestrol acetate; Compound label in the paper: MA

Experimental findings for the named acetate form; no equivalence to an Adooq lot or clinical formulation is established.

Methods: Animals; Study design; Spontaneous activity and food intake; Echocardiographic analysis; Statistical analysis. Results: survival, morbidity and cardiac dysfunction; Figures 1, 3 and 4.

Left ventricular ejection fraction on day 11: Echocardiography; original Results provide numerical values, Figure 4B provides visual/statistical check — Methods: Echocardiographic analysis and Statistical analysis; Results: Megestrol acetate improves tumour-induced cardiac dysfunction and heart wasting; Figure 4B

Survival over maximum 16-day study: Cox proportional hazards analysis; MA versus tumor-bearing placebo — Methods: Statistical analysis; Results: Megestrol acetate improves survival in cancer cachexia; Figure 1

Food intake, spontaneous activity, cardiac volumes and tumor growth: 24-h food intake and infrared activity monitoring on day 11; echocardiography on day 11; terminal tumor assessment — Results: survival (tumor-growth null finding), Indices of morbidity; Figure 3A–B; cardiac dysfunction Results and Figure 4D,F

Megestrol acetate · Methods: Study design; Results: survival and cardiac dysfunction; Figures 1 and 4B

Tumor-bearing placebo · Methods: Study design; Results: survival and cardiac dysfunction; Figures 1 and 4B

Specifications

Manufacturer Adooq Bioscience
CAS Number 595-33-5
Formula C24H32O4
Molecular Weight 384.51
SMILES
CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 30 mg/mL (78.02 mM)
Water Insoluble
Ethanol 14 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Megestrol Acetate Research References

  1. [1] House L, Seminerio MJ, Mirkov S, et al. Metabolism of megestrol acetate in vitro and the role of oxidative metabolites Xenobiotica; the fate of foreign compounds in biological systems (2018). PMID: 29050522 DOI: 10.1080/00498254.2017.1386335 Source material
  2. [2] Sung JH, An HS, Jeong JH, et al. Megestrol Acetate Increases the Proliferation, Migration, and Adipogenic Differentiation of Adipose-Derived Stem Cells via Glucocorticoid Receptor Stem cells translational medicine (2015). PMID: 25972147 DOI: 10.5966/sctm.2015-0009 Source material
  3. [3] Musolino V, Palus S, Tschirner A, et al. Megestrol acetate improves cardiac function in a model of cancer cachexia-induced cardiomyopathy by autophagic modulation Journal of cachexia, sarcopenia and muscle (2016). PMID: 27239419 DOI: 10.1002/jcsm.12116 Source material

Publications

1 publication citing this product

  1. Hong Wang, .et al. , Exp Biol Med (Maywood), 2021, Jul 7 PMID: 34233525

Added to your cart

View Cart Checkout
Loading...